Parathyroid Disease Treatment Market Report 2025

The parathyroid disease treatment market size has grown strongly in recent years. It will grow from $2.21 billion in 2024 to $2.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be attributed to the rising prevalence of chronic kidney disease, increasing cases of osteoporosis, heightened awareness of endocrine disorders, expansion of diagnostic capabilities, and improved access to specialty healthcare.

The parathyroid disease treatment market size is expected to see strong growth in the next few years. It will grow to $3.1 billion in 2029 at a compound annual growth rate (CAGR) of 7%. The projected growth in the forecast period can be linked to the increasing aging population, greater use of non-surgical treatments, a rising incidence of postmenopausal bone disorders, government initiatives targeting rare disease management, and wider adoption of minimally invasive parathyroidectomy. Key trends expected during this time include a move toward personalized hormone therapies, development of long-acting hormone analogs, incorporation of AI in endocrine diagnostics, focus on drugs targeting calcium-sensing receptors, and advancements in parathyroid hormone analogs.

The increasing prevalence of chronic kidney disease (CKD) is expected to drive growth in the parathyroid disease treatment market. CKD is a progressive condition where kidney function declines over time, causing mineral imbalances like calcium and phosphorus. This rise in CKD cases is largely attributed to the growing incidence of diabetes, as prolonged high blood sugar levels can damage the kidneys' filtering units, leading to diabetic nephropathy. Treating parathyroid disease is crucial for managing CKD, particularly to address secondary hyperparathyroidism, a common complication in advanced CKD that disrupts mineral balance, contributes to bone disorders, and causes vascular calcification. For example, in June 2024, the Australian Institute of Health and Welfare reported that CKD mortality rates increased by 4.2% in 2021 and 6.2% in 2022. In 2022, CKD was responsible for approximately 22,000 deaths, accounting for 11% of all deaths in Australia, with a mortality rate of 84 per 100,000 people. Hence, the growing prevalence of CKD is fueling the parathyroid disease treatment market.

Companies in the parathyroid disease treatment market are advancing hormone replacement therapies by developing parathyroid hormone prodrugs that improve calcium regulation and reduce dosing frequency for hypoparathyroidism patients. Parathyroid hormone (PTH) prodrugs are inactive compounds that activate in the body to help maintain calcium and phosphate balance. For instance, in August 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical firm, received FDA approval for YORVIPATH (palopegteriparatide), a PTH prodrug for treating chronic hypoparathyroidism in adults. This once-daily treatment offers continuous hormone exposure over 24 hours, providing an alternative to traditional calcium and vitamin D supplements by directly addressing hormone deficiency. The approval of YORVIPATH highlights the growing focus on innovative hormone replacement therapies to improve treatment adherence and clinical outcomes for patients with parathyroid disorders.

In July 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Amolyt Pharma SAS for $1.05 billion. This acquisition is intended to enhance AstraZeneca’s Alexion Rare Disease portfolio by advancing its late-stage pipeline and expanding its bone metabolism franchise with eneboparatide (AZP-3601), a Phase III investigational drug for hypoparathyroidism treatment. Amolyt Pharma SAS is a France-based clinical-stage biotech company specializing in developing novel therapies for rare endocrine diseases, including parathyroid disorders such as hypoparathyroidism.

Major players in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Teijin Pharma Limited, Kyowa Kirin Co. Ltd., Shandong Buchang Pharmaceuticals Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., STERIS Healthcare Private Limited, Crinetics Pharmaceuticals Inc., Amorphical Ltd., Vidasym Inc., Extend Biosciences Inc., Rani Therapeutics LLC, Pathalys Pharma Inc., and ProLynx LLC.

Asia-Pacific was the largest region in the parathyroid disease treatment market in 2024. The regions covered in parathyroid disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the parathyroid disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The parathyroid disease treatment market consists of revenues earned by entities by providing services such as diagnostic testing, surgical intervention, hormone level monitoring, post-operative care, and medical management of calcium and phosphate balance. The market value includes the value of related goods sold by the service provider or included within the service offering. The parathyroid disease treatment market also includes sales of lanthanum carbonate, doxercalciferol, calcitriol, lanthanum carbonate, and parsabiv. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The parathyroid disease treatment market research report is one of a series of new reports that provides parathyroid disease treatment market statistics, including the parathyroid disease treatment industry global market size, regional shares, competitors with the parathyroid disease treatment market share, detailed parathyroid disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the parathyroid disease treatment industry. These parathyroid disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Parathyroid disease treatment involves medical and surgical methods aimed at managing disorders of the parathyroid glands, small endocrine glands in the neck responsible for regulating calcium and phosphorus levels in the body by secreting parathyroid hormone (PTH).

The primary treatment options for parathyroid disease include calcimimetics, bisphosphonates, plicamycin, hormone replacement therapy, and other therapies. Calcimimetics are medications that lower parathyroid hormone (PTH) levels by mimicking calcium and stimulating calcium-sensing receptors on the parathyroid glands. These drugs can be administered orally or parenterally and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. They are utilized by a range of end-users, including hospitals, homecare settings, specialty centers, and others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.